• 제목/요약/키워드: Antifibrinolytic therapy

검색결과 6건 처리시간 0.028초

조기 뇌동맥류 수술전에 항섬유소융해제 치료의 이점 (Benefits of Antifibrinolytic Therapy before Early Aneurysm Surgery)

  • 김종문;강성돈
    • Journal of Korean Neurosurgical Society
    • /
    • 제30권6호
    • /
    • pp.729-733
    • /
    • 2001
  • Objective : Antifibrinolytic treatment after aneurysmal subarachnoid hemorrhage has been shown to have no significant effect on outcome since a reduction in the rate of rebleeding was offset by an increase in the incidence of hydrocephalus and ischemic events. As the results of early aneurysm surgery and a change of strategy in the intensive medical treatment, outcome in patients with cerebral ischemia has been improved. On the other hand, rebleeding still remains as a major cause of death. A short course of tranexamic acid(TA) was tried to study its efficacy and safety in reducing the incidence of rebleeding before aneurysm surgery. Methods : A total of 507 patients with ruptured cerebral aneurysm operated within 3 days after the attack from 1990 to 1999 were included in this study. Group A consisted of 302 consecutive patients treated from 1990 through 1995 served as control. Two hundred-five patients in group B were treated with TA from 1996 through 1999. Both groups were evaluated for comparability of demographic and clinical variables including age, Hunt-Hess grade, Fisher grade, aneurysm location, hypertension, day of surgery, and initial hydrocephalus. The relationships of TA with rebleeding, ischemia, and chronic hydrocephalus were also studied. Results : There was no significant difference in patient demographics and clinical characteristics between group A and group B. Sixteen patients(5.3%) suffered a recurrent hemorrhage in group A and three(1.5%) in group B(p<0.05). Chronic hydrocephalus requiring a shunt was found in a significantly greater proportion in group B than in group A(p<0.05). The incidence of cerebral ischemia was not elevated in group B compared with group A. Conclusion : Considering the fact that the reduction of fatal rebleeding outweighed the increased incidence of hydrocephalus, the authors believe that a short course of TA is beneficial in diminishing the risk of rebleeding prior to early surgical intervention.

  • PDF

응고인자 투여와 surgical splint를 이용한 혈우병 환자의 발치 치험례 (TOOTH EXTRACTION USING REPLACEMENT THERAPY AND SURGICAL SPLINT IN HEMOPHILIAC PATIENT)

  • 이재문;남순현;김영진
    • 대한소아치과학회지
    • /
    • 제23권3호
    • /
    • pp.575-581
    • /
    • 1996
  • Hemophilia is a hereditary condition in which one of the normal blood clotting factors is absent. This sex-linked, recessive disease, transmitted by the female and expressed in some of her male offspring, is characterized by significantly delayed coagulation times and by the tendency to hemorrhage. On the dental treatment especially, surgical procedure, appropriate methods of hemorrhage control are required. These methods are replacement therapy, antifibrinolytic agents, and local hemostatic methods. In this case, we successfully extract residual roots of hemophiliac patient without eccessive post operative bleeding using replacement therapy and surgical splint.

  • PDF

혈관신경성부종의 문헌적 고찰 및 증례 보고 (ANGIONEUROTIC EDEMA REVIEW OF REFERENCES AND A CASE REPORT)

  • 김온;서보영;김성문;임재석
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • 제11권1호
    • /
    • pp.231-236
    • /
    • 1989
  • Angioneurotic edema is rarely seen in dental practice and manifested by acute attacks of swelling of the extremities, face, airway, or abdominal visera, occuring spontaneously and suddenly or secondary to trauma. Two types are recognized : hereditary and nonhereditary. Prophylatic therapy may be used by fresh frozen plasma or antifibrinolytic agents in hereditary type. Good supportive care for acute attacks, together with a knowledge of course of the disease, can prevent asphyxiation from airway obstruction. A case of acute angioneurotic edema of the facial area in a 19-year-old man is presented in conjunction with a review of the literature. Angioneurotic edema attacks him acutely after the extraction of the lower, right 3rd molar.

  • PDF

혈우병 B 환아의 전신마취 하 치과치료 : 증례보고 (DENTAL MANAGEMENT OF CHILDREN WITH HEMOPHILIA UNDER THE GENERAL ANESTHESIA : A CASE REPORT)

  • 김수경;박재홍;이긍호;김광철;최성철
    • 대한장애인치과학회지
    • /
    • 제4권1호
    • /
    • pp.7-11
    • /
    • 2008
  • 치과의사는 혈우병 환자의 치료 시 주의사항에 대해 잘 알고 있어야 한다. 혈우병 환자의 내원 시 소아과 의사 및 혈우재단 등 전문가에게 의뢰하여 환자의 상태에 대한 자문을 얻어야 하고, 치과 치료 시 적절한 계획 하에 최소의 침습적인 치료가 행해지도록 노력해야 하며, 응급 상황을 대비하여 지혈방법을 습득해야 한다. 또 환자와 보호자에게 평소 구강 관리의 중요성을 일깨워 침습적 치과 치료의 빈도를 줄일 수 있도록 해야 한다.

  • PDF

뇌동맥류의 조기수술 전 재출혈 방지를 위한 항섬유소용해제 투여의 효과 (The Effect of Antifibrinolytic Therapy in Prevention of Rebleeding before Early Aneurysm Surgery)

  • 이창영;임만빈;이장철;손은익;김동원;김인홍
    • Journal of Korean Neurosurgical Society
    • /
    • 제30권9호
    • /
    • pp.1065-1071
    • /
    • 2001
  • 파열된 뇌동맥류의 조기수술이 계획된 환자에서 수술전까지 단기간에 걸친 항섬유소용해제 투여의 효과를 알아보기 위해 뇌동맥류성 지주막하출혈 환자 137례에 대하여 60례를 AMCA 투여군으로, 77례를 비 투여군으로 분류하여 재출혈, 증상적 혈관연축, 뇌수두증의 발생빈도 및 전체적인 치료성적을 비교, 분석하였다. 재출혈의 발생빈도는 AMCA 비 투여군에 비해 투여군에서 통계학적으로 유의하게 낮게 나타났고 AMCA의 장기투여에서 증가를 보인 증상적 혈관연축과 뇌수두증의 발생빈도는 양군에서 유의한 차이를 보이지 않았으며 전체적인 치료성적은 AMCA 투여군에서 비 투여군에 비해 보다 양호한 결과를 보였다. 따라서 조기수술이 계획된 뇌동맥류성 지주막하출혈 환자에서 AMCA의 단기간 투여는 재출혈율을 감소시켜 전체적인 치료결과를 향상시키는데 도움이 될 것으로 생각된다.

  • PDF

Role of Adjunctive Tranexamic Acid in Facilitating Resolution of Chronic Subdural Hematoma after Surgery

  • Kiyoon Yang;Kyung Hwan Kim;Han-Joo Lee;Eun-Oh Jeong;Hyon-Jo Kwon;Seon-Hwan Kim
    • Journal of Korean Neurosurgical Society
    • /
    • 제66권4호
    • /
    • pp.446-455
    • /
    • 2023
  • Objective : Chronic subdural hematoma (CSDH) is a common neurosurgical disease and generally treated with burr-hole surgery alone. Tranexamic acid (TXA) is an antifibrinolytic agent that potentially reduces recurrence rates and the residual hematoma volume. However, the role of postoperative TXA medication remains unclear to date. This study aimed to verify the effectiveness of adjunctive TXA in the view of early hematoma resolution. Methods : Between January 2018 and September 2021, patients with CSDH who underwent burr-hole trephination in a single tertiary institute were reviewed. The study population was divided into three groups, TXA, non-TXA, and antithrombotics (AT) groups, according to the medical history of cardio-cerebrovascular disease and TXA administration. The primary endpoint was CSDH recurrence, defined as re-appearance or re-accumulation of CSDH requiring neurosurgical interventions. The secondary outcome was CSDH resolution, defined as complete or near-complete resorption of the CSDH. The CSDH resolution time and serial changes of hematoma thickness were also investigated. Results : A total of 240 patients was included in the analysis consisting of 185 male and 55 female, with a median age of 74 years. During the median imaging follow-up period of 75 days, 222 patients were reached to the primary or secondary endpoint. TXA was administered as an adjunctive therapy in 41 patients (TXA group, 16.9%) while 114 patients were included in the non-TXA group (47.9%) and 85 were in the AT group. The recurrence rate was the lowest in the TXA group (2.4%), followed by non-TXA (7.0%) and AT (8.2%) groups. However, there was no statistical significance due to the small number of patients with recurrence. CSDH resolution was achieved in 206 patients, and the median estimated time to resolution was significantly faster in the TXA group (p<0.001). Adjunctive TXA administration was a significant positive factor for achieving CSDH resolution (p<0.001). The hematoma thickness was comparable among the three groups at the initial time and after surgery. However, CSDH thickness in the TXA group decreased abruptly in a month and showed a significant difference from that in the other groups (p<0.001). There was no TXA-related adverse event. Conclusion : The adjunctive use of TXA after CSDH surgery significantly facilitated the resorption of residual CSDH and resulted in the early CSDH resolution. Adjunctive TXA may be an effective treatment option to reduce recurrence by enhancing CSDH resolution in the selective patients.